Recent Blog Posts

View Post: Patent Docs: Court Report
15 Nov 2009 by Patent Docs  
... 2008) following a Paragraph IV certification as part of Alcon's filing of an ANDA to manufacture a generic version of Allergan's Combigan® (brimonidine tartrate/timolol maleate ophthalmic solution, used to treat glaucoma). ...
View Blog: Patent Docs - http://www.patentdocs.org/

---

View Post: Allergan Announces Victory in Brimonidine Patent Infringement Case ...
25 Oct 2009
("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in ... ALPHAGAN® P 0.1% and 0.15% are indicated for lowering elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension. ALPHAGAN® P 0.1% and 0.15% are contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy. ...
View Blog: Pharmaceutical Jobs - Pharmaco - http://www.pharmiweb.com/

---

View Post: Allergan, Inc. Receives FDA Approval for Combigan (brimonidine ...
31 Oct 2007
Combigan is the newest addition to Allergan's comprehensive glaucoma portfolio, which also includes Lumigan (bimatoprost ophthalmic solution) 0.03% and Alphagan P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. ...
View Blog: Drugs.com - New Drug Approvals - http://www.drugs.com/newdrugs.html

---

View Post: Alphagan-P (Brimonidine Tartrate) Drug Information: Uses, Side ...
3 Apr 2009
In a well-controlled clinical study conducted in pediatric glaucoma patients (ages 2 to 7 years) the most commonly observed adverse events with brimonidine tartrate ophthalmic solution 0.2% dosed three times daily were somnolence ...
View Blog: RxList - News and Features - http://www.rxlist.com/script/main/hp.asp

---

View Post: Lumigan X EU Committee Recomendation - GLG News
27 Oct 2009 by Andrew Dahl  
The Committee for Medicinal Products for Human Use (CHMP) of the European Union has recommended granting a Marketing Authorization for a new version of Allergan's Lumigan (bimatoprost ophthalmic solution). This new version will be marketed as Lumigan-X after approval. ... Allergan's ill-advised manipulation of concentrations with their Alphagan (brimonidine) product by bringing out Alphagan-P did not take market share from its competitors within the glaucoma space. ...
View Blog: GLG News(sm): Healthcare - http://www.glgroup.com/Council-News-Listing/Healthcare-1.html

---

View Post: FDA Approvals: Combigan and Tasigna
8 Nov 2007
On October 30, the FDA approved brimonidine tartrate/timolol maleate 0.2%/0.5% topical ophthalmic solution ( Combigan; Allergan, Inc) to reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require ...
View Blog: Medscape Ophthalmology Headlines - http://www.medscape.com/ophthalmology?src=rss

---

View Post: Aton Pharma acquires Timoptic product line - MPR
16 Mar 2009
The Timoptic product line includes Timoptic (timolol maleate) ophthalmic solution, Timoptic Ocudose (timolol maleate) ophthalmic solution in a sterile ophthalmic unit dose dispenser, and Timoptic-XE (timolol maleate) ophthalmic gel forming solution. ... Eye Disorders > Glaucoma. α2-AGONISTS: The α2-agonists (eg, brimonidine, apraclonidine) reduce aqueous humor production and increase uveoscleral outflow to lower intraocular pressure (IOP). By . ...
View Blog: Latest articles from MPR - http://www.empr.com/

---

View Post: Combigan Drops Approved for Glaucoma
31 Oct 2007
WEDNESDAY, Oct. 31 (HealthDay News) -- The U.S. Food and Drug Administration has approved Combigan eye drops (brimonidine tartrate/timolol maleate ophthalmic solution) to treat elevated intraocular pressure (IOP) in people with glaucoma ...
View Blog: Eye Care - http://www.dentalplans.com/articles_rss/categoryrss25.xml

---

View Post: Recent advances in pharmacotherapy of glaucoma Gupta SK, Galpalli ...
21 Nov 2008 by Gupta SK, Galpalli Niranjan D, Agrawal...  
Brimonidine Brimonidine is the a-2 agonist of choice in glaucoma treatment, which acts by decreasing the aqueous humor secretion and increasing the uveoscleral outflow. It does not cross the blood-brain barrier and is 30 times more selective for the ... Timolol is the US-FDA's gold standard drug for glaucoma therapy, against which all new medications must be compared prior to approval. Carteolol Carteolol hydrochloride [Figure 4] ophthalmic solution, 1%, is a nonselective ...
View Blog: Table of Contents : Indian Journal of Pharmacol... - http://www.ijp-online.com/currentissue.asp

---